| Budget Amount *help |
¥5,070,000 (Direct Cost: ¥3,900,000、Indirect Cost: ¥1,170,000)
Fiscal Year 2015: ¥1,170,000 (Direct Cost: ¥900,000、Indirect Cost: ¥270,000)
Fiscal Year 2014: ¥1,820,000 (Direct Cost: ¥1,400,000、Indirect Cost: ¥420,000)
Fiscal Year 2013: ¥2,080,000 (Direct Cost: ¥1,600,000、Indirect Cost: ¥480,000)
|
|---|
| Outline of Final Research Achievements |
Pioglitazone, a thiazolidinedione (TZD), is widely used as an insulin sensitizer in the treatment of type 2 diabetes. However, body weight gain is frequently observed in TZD-treated patients. Fish oil improves lipid metabolism dysfunction and obesity. We demonstrated that the combination of pioglitazone and fish oil may prevent the adverse effects of pioglitazone on promoting excessive body weight gain and subcutaneous fat accumulation. And, this study showed that fish oil and pioglitazone effectively prevented hypertrophy of the pancreatic islets and apoptosis-induced cell death through increased insulin sensitivity and decreased ER stress. The reduction of β-cell dysfunction by fish oil and pioglitazone may be leaded to the suppression of systemic oxidative stress because of decreased visceral fat levels.
The results suggest that the combination of pioglitazone and fish oil has particular efficacy in diabetic patients with fatty liver and adipose tissue inflammation.
|
